Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 2:51 PM ET


Company Overview of Igenica, Inc.

Company Overview

Igenica, Inc., a biopharmaceutical company, engages in the discovery and development of antibody-based therapeutics for the treatment of cancer. It develops recombinant monoclonal antibodies and treatments for multiple oncology indications. The company was founded in 2008 and is based in Burlingame, California.

863 Mitten Road

Suite 102

Burlingame, CA 94010

United States

Founded in 2008



Key Executives for Igenica, Inc.

Executive Chairman
Age: 63
Chief Business Officer
Vice President of Research
Vice President of Process Development
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Igenica, Inc. Key Developments

Igenica Biotherapeutics Signs Oncology Research Deal with MedImmune

Igenica Biotherapeutics has signed an oncology research agreement with AstraZeneca's subsidiary MedImmune. The companies will assess the potential of antibody-drug conjugates (ADCs) targeting Surface Antigen in Leukemia (SAIL). SAIL is a novel cell surface protein with high prevalence of expression in several hematologic malignancies and solid tumors. Preclinical data have supported the selective targeting of tumors expressing SAIL with ADCs. Igenica will provide its anti-SAIL antibodies, including IGN786, and its SNAP ADC drug linker, while MedImmune will contribute its anti-tumor payload. Both the companies will then jointly investigate the resulting novel ADC in preclinical studies. MedImmune will have an option to an exclusive worldwide license to anti-SAIL antibodies and antibody-drug conjugates that arise from the partnership. Igenica will have an exclusive option fee. If MedImmune exercises its option, the company will also receive an upfront license fee, clinical, regulatory and commercialization milestones, and royalties on net sales. The development and commercialization costs will be funded by MedImmune under a license agreement.

Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015

Igenica Biotherapeutics, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Igenica, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 04:10 PM

Igenica, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 04:10 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Mary Haak-Frendscho, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Intarcia Therapeutics, Inc. United States
Celsense, Inc. United States
NeuroCorp., Ltd. United States
Genomas, Inc. United States
Accellient Partners, LLC United States

Recent Private Companies Transactions

Private Placement
September 29, 2015
Private Placement
May 22, 2015
Private Placement
January 8, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Igenica, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at